over, the cancer is slow growing, with a period of about 20-25 years from initiation to the stage when the clinically detectable phenotype can be identified. This review provides a simple overview of the endocrinology of prostate cancer and discusses some of the pharmaceutical agents that have been or are being tested to restrain, possibly arrest, the progression of this slowly growing cancer. Also discussed are many of the dietary factors that may influence the molecular or endocrine events implicated in its development. Dietary factors are considered responsible for the geographical differences in prostate cancer incidence and mortality. Since about 50% of all men worldwide, from both East and West, show evidence of microscopic cancer by 50 years of age, growth restraint would appear to be the pragmatic option to the possibility of preventing initiation.
Some Introductory Perspectives
The concept that prostate cancer is preventable is by no means new. Questions posed by Huggins [1] at one of the earliest meetings to specifically discuss the biology of the gland are still relevant. He highlighted certain unresolved problems (Fig. 4.1 ) that today continue to exercise the minds of investigators, none more so than the reasons for the geographical differences in the incidence of prostate cancer. The disease is prevalent in Western developed countries, but rare in Asia [2] . Until recently the concept that dietary variability could influence the pathogenesis of cancer was considered with scepticism, but now interest centres on whether worldwide variability is caused by dietary factors such as the high intake of fat in the West, or prevented by particular constituents of the Asian diet.
Many constituents could impinge on the molecular events implicated in prostate carcinogenesis to provide health benefit [3, 4] , and interest in chemoprevention has increased spectacularly. As our understanding of prostate growth regulation dramatically develops [5] [6] [7] [8] , potential roles for dietary factors become easier to appreciate [4, 9, 10] and there is little doubt that geographical differences in diet and lifestyle account for a large part of the worldwide variability in incidence.
The Natural History of Prostate Cancer
Prostate cancer is a disease of middle-aged men which presents clinically beyond 50 years of age and involves a slowly growing tumour that takes more than 25 years to develop from a focal lesion to the malignant phenotype (Fig. 4.2) . Once outside the confines of the capsule, the disease is incurable. Its natural history is characterised by a 20-year development phase, followed by a 10-year preclinical, asymptomatic period. Secondary prevention through early diagnosis using serum prostate-specific antigen (PSA) analysis and prostate biopsy has dramatically increased incidence rates during the preclinical period, creating interest in population screening. The results of international randomised screening trials are awaited [11] .
Particularly important, however, is that the preclinical period offers the potential for primary chemoprevention, which will probably not prevent initiation but certainly could suppress the rate of cancer growth and progression. The natural history highlights phases where preventive strategies can be focussed. 
